PMID- 38255717
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240129
IS  - 2075-1729 (Print)
IS  - 2075-1729 (Electronic)
IS  - 2075-1729 (Linking)
VI  - 14
IP  - 1
DP  - 2024 Jan 9
TI  - Understanding the Mode of Action of a Micro-Immunotherapy Formulation: 
      Pre-Clinical Evidence from the Study of 2LEBV((R)) Active Ingredients.
LID - 10.3390/life14010102 [doi]
LID - 102
AB  - BACKGROUND: Epstein-Barr virus (EBV) is often kept silent and asymptomatic; 
      however, its reactivation induces a chronic and/or recurrent infection that is 
      associated with numerous diseases, including cancer and inflammation-related 
      disorders. As no specific treatment is currently available, the immune 
      factors-based micro-immunotherapy (MI) medicine 2LEBV((R)) could be considered a 
      valuable therapeutic option to sustain the immune system in EBV reactivation. 
      METHODS: The present work aimed to investigate, for the first time, the effect of 
      2LEBV((R)) in several in vitro models of uninfected immune-related cells. RESULTS: 
      2LEBV((R)) displayed phagocytosis-enhancing capabilities in granulocytes. In human 
      peripheral blood mononuclear cells (PBMCs), it increased the intra- and 
      extra-cellular expression of interleukin (IL)-2. Moreover, it modulated the 
      secretion of other cytokines, increasing IL-4, IL-6, and tumor necrosis factor-alpha 
      levels or lowering other cytokines levels such as IL-9. Finally, 2LEBV((R)) reduced 
      the expression of human leukocyte antigen (HLA)-II in endothelial cells and 
      macrophages. CONCLUSIONS: Although these data are still preliminary and the 
      chosen models do not consider the underlying EBV-reactivation mechanisms, they 
      still provide a better understanding of the mechanisms of action of 2LEBV((R)), 
      both at functional and molecular levels. Furthermore, they open perspectives 
      regarding the potential targets of 2LEBV((R)) in its employment as a therapeutic 
      intervention for EBV-associated diseases.
FAU - Jacques, Camille
AU  - Jacques C
AUID- ORCID: 0000-0002-8044-0545
AD  - Pre-Clinical Research Department, Labo'Life France, Pescalis-Les Magnys, 79320 
      Moncoutant-sur-Sevre, France.
FAU - Marchand, Flora
AU  - Marchand F
AD  - ProfileHIT, 7 rue du Buisson, 44680 Sainte-Pazanne, France.
FAU - Chatelais, Mathias
AU  - Chatelais M
AD  - ProfileHIT, 7 rue du Buisson, 44680 Sainte-Pazanne, France.
FAU - Brulefert, Adrien
AU  - Brulefert A
AD  - QIMA Life Sciences, 1 bis rue des Plantes-CS 50011, 86160 Gencay, France.
FAU - Floris, Ilaria
AU  - Floris I
AUID- ORCID: 0000-0003-4089-3133
AD  - Pre-Clinical Research Department, Labo'Life France, Pescalis-Les Magnys, 79320 
      Moncoutant-sur-Sevre, France.
LA  - eng
PT  - Journal Article
DEP - 20240109
PL  - Switzerland
TA  - Life (Basel)
JT  - Life (Basel, Switzerland)
JID - 101580444
PMC - PMC10821216
OTO - NOTNLM
OT  - EBV-associated diseases
OT  - Epstein-Barr virus
OT  - cytokines
OT  - immunotherapy
OT  - interleukin-2
OT  - micro-immunotherapy
COIS- The authors declared the following conflicts of interest with respect to the 
      research, authorship, and/or publication of this article: Camille Jacques and 
      Ilaria Floris work for Labo'Life France, the company service provider of 
      Labo'Life, which specializes in preclinical research and regulatory affairs. This 
      professional relationship does not imply any misconduct on the part of the 
      authors. Mathias Chatelais and Flora Marchand work for ProfileHIT, an innovative 
      profiling company involved in the vascular and immunology crosstalk research 
      field in humans. Adrien Brulefert works for QIMA Life Sciences, a company 
      specializing in biotechnologies.
EDAT- 2024/01/23 06:43
MHDA- 2024/01/23 06:44
PMCR- 2024/01/09
CRDT- 2024/01/23 01:10
PHST- 2023/11/10 00:00 [received]
PHST- 2024/01/04 00:00 [revised]
PHST- 2024/01/05 00:00 [accepted]
PHST- 2024/01/23 06:44 [medline]
PHST- 2024/01/23 06:43 [pubmed]
PHST- 2024/01/23 01:10 [entrez]
PHST- 2024/01/09 00:00 [pmc-release]
AID - life14010102 [pii]
AID - life-14-00102 [pii]
AID - 10.3390/life14010102 [doi]
PST - epublish
SO  - Life (Basel). 2024 Jan 9;14(1):102. doi: 10.3390/life14010102.